Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the...

INDIANAPOLIS, July 2, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL...

TUESDAY, July 2, 2024 -- A new drug to treat Alzheimer's disease was approved by the U.S. Food and Drug Administration on Tuesday. In clinical trials,...

July 2 - The U.S. Food and Drug Administration on Tuesday gave a green light to Eli Lilly's LLY.N donanemab for patients with early Alzheimer's,...

The U.S. Food and Drug Administration (FDA) has approved a new Alzheimer's treatment from American pharmaceutical company Eli Lilly. The U.S....

By Matthew Perrone | AP Health Writer

The Subject Expert Committee (SEC), which advises the national drug regulator on drugs and trials approval matters, has recommended grant of...

Alzheimer’s disease is a progressive brain disorder that affects memory, thinking, and behavior. It’s the most common cause of dementia in older...

LONDON and RALEIGH, N.C., June 26, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the...

Approval from the FDA not only validates the safety and efficacy of a new drug, but also opens the door ...